Rosetta Agrees to Buyout from Merck

Ameritrade up for sale?; Merrill sees opportunity in Universal Compression; and more stocks in the news

Rosetta Inpharmatics (RSTA ) agreed to be acquired by Merck & Co. (MRK ) in a roughly $620 million stock deal. Terms: 0.2352 Merck share per Rosetta share.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.